Skip to content
10-Q

Quarterly Report

Curanex Pharmaceuticals Inc CURX

0001493152-26-022892

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 28.36M sh
Shares Diluted Q1 2026 · Mar 31, 2026 28.34M sh
Shares Diluted Q1 2026 · Mar 31, 2025 24M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$954.56K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$149.95K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $4M
Stockholders Equity Q1 2026 · Mar 31, 2026 $8.08M
Stockholders Equity Q1 2026 · Dec 31, 2025 $11.22M
Stockholders Equity Q1 2026 · Mar 31, 2025 $365.78K
Stockholders Equity Q1 2026 · Dec 31, 2024 $503.36K
Current Liabilities Q1 2026 · Mar 31, 2026 $128.73K
Current Liabilities Q1 2026 · Dec 31, 2025 $137.03K
Total Liabilities Q1 2026 · Mar 31, 2026 $332.64K
Total Liabilities Q1 2026 · Dec 31, 2025 $361.04K
Current Assets Q1 2026 · Mar 31, 2026 $8.09M
Current Assets Q1 2026 · Dec 31, 2025 $11.23M
Total Assets Q1 2026 · Mar 31, 2026 $8.41M
Total Assets Q1 2026 · Dec 31, 2025 $11.58M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.11
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.01
Eps Basic Q1 2026 · Mar 31, 2026 −$0.11
Eps Basic Q1 2026 · Mar 31, 2025 −$0.01
Sga Expense Q1 2026 · Mar 31, 2026 $927.2K
Sga Expense Q1 2026 · Mar 31, 2025 $137.45K
Rd Expense Q1 2026 · Mar 31, 2026 $2.26M
Net Income Q1 2026 · Mar 31, 2026 −$3.15M
Net Income Q1 2026 · Mar 31, 2025 −$137.58K
Operating Income Q1 2026 · Mar 31, 2026 −$3.18M
Operating Income Q1 2026 · Mar 31, 2025 −$137.45K